Brian Smith
Psychiatric/Mental Health · Springfield, MONPI 1790377075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 537 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$907
- AbbVie$891
- Teva Pharmaceuticals USA, Inc.$629
- Alkermes, Inc.$548
- plus $4K from 19 others
What the payments were for
- Food & beverage$9,40499%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 130 | $1,817 |
| Otsuka America Pharmaceutical, Inc. | 57 | $1,110 |
| Axsome Therapeutics, Inc. | 25 | $907 |
| AbbVie | 41 | $891 |
| Teva Pharmaceuticals USA, Inc. | 60 | $629 |
| Alkermes, Inc. | 28 | $548 |
| Johnson & Johnson | 17 | $491 |
| Indivior Inc. | 25 | $464 |
| Neurocrine Biosciences, Inc. | 22 | $436 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $413 |
| E.r. Squibb & Sons, L.L.C. | 18 | $393 |
| Corium, LLC | 12 | $288 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $192 |
| Pfizer | 18 | $169 |
| Lundbeck LLC | 8 | $147 |
| Sunovion Pharmaceuticals Inc. | 10 | $137 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $136 |
| Avanir Pharmaceuticals, Inc. | 4 | $64 |
| Merck | 4 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Almatica Pharma LLC | 2 | $43 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Gilead | 1 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$497
- QELBREE$251
- ABILIFY MAINTENA$250
- COBENFY$135
- ABILIFY ASIMTUFII$125
- REXULTI$125
- VRAYLAR$123
- INVEGA SUSTENNA$112
- INVEGA TRINZA$112
How this compares
$9,507 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 44 | $336,023 |
| VraylarCariprazine Hcl | 84 | $126,170 |
| Abilify MaintenaAripiprazole | 35 | $108,741 |
| Invega SustennaPaliperidone Palmitate | 29 | $92,495 |
| IngrezzaValbenazine Tosylate | 11 | $90,735 |
| RexultiBrexpiprazole | 40 | $73,549 |
| AristadaAripiprazole Lauroxil | 19 | $62,405 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $54,066 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $36,763 |
| CaplytaLumateperone Tosylate | 15 | $27,475 |
| TrintellixVortioxetine Hydrobromide | 51 | $27,233 |
| Aripiprazole | 239 | $25,947 |
| Clozapine | 56 | $9,894 |
| Paliperidone ErPaliperidone | 63 | $8,428 |
| Lurasidone Hcl | 70 | $7,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $629 | $336,02344 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,110 | $182,29075 claims |
| AbbVieVraylar | $891 | $126,17084 claims |
| Alkermes, Inc.Aristada, Lybalvi | $548 | $99,16847 claims |
| Johnson & JohnsonInvega Sustenna | $491 | $92,49529 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $436 | $90,73511 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $64 | $54,06632 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $413 | $27,47515 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $192 | $27,23351 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $32 | $5,54115 claims |
| MerckBelsomra | $58 | $4,85311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Springfield
- Erin DuvallSpringfield$275K
- Emily WoukSpringfield$90K
- Karin BaughmanSpringfield$16K
- Tedra EstisSpringfield$13K
- Ashlee RossnerSpringfield$8K
- Holly JulianSpringfield$6K
- Kendra RasmussenSpringfield$6K
- Aldijana SacicSaint Louis$510K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.